Cel-Sci Corp.

+0.76 (+3.53%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)976.15M
Current PEN/A
Forward PE N/A
2yr Forward PE 21.21
See more stats
Estimates Current Quarter
Revenue$0.1 Million
Adjusted EPS-$0.13
See more estimates
10-Day MA$21.93
50-Day MA$21.29
200-Day MA$16.82
See more pivots

Cel-Sci Corp. Stock, ASE:CVM

8229 Boone Boulevard, Suite 802, Vienna, Virginia 22182
United States of America
Phone: +1.703.506.9460
Number of Employees:


CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.